Eli Lilly Expands Its In Vivo Ambitions, Acquiring Cell Therapy Startup Orna for up to $2.4B – MedCity News
The next frontier for cell therapy is shaping up to be in vivo treatments for autoimmune disease, and Eli Lilly…
The next frontier for cell therapy is shaping up to be in vivo treatments for autoimmune disease, and Eli Lilly…
Drug discovery, the art of identifying new molecules to develop pharmaceuticals, is a notoriously time-consuming and difficult process. Traditional techniques,…
AI healthcare concept stocks in the Hong Kong stock market collectively surged, $FANGZHOU JIANKE (06086.HK)$ with some rising over 36%,…
Michelle Carnahan spent four years as the president of VC-backed healthcare startup Thirty Madison, and before that, had a two-decade-long…
Eli Lilly (NYSE:LLY) just pre-announced a $1.57 billion pre-tax charge related to acquired in-process R&D, which is expected to weigh…